Lung Cancer: Targets and Therapyhttps://www.dovepress.com/feed/journal/83New articles released by Dove Press for Lung Cancer: Targets and Therapyen-us2026, Dove Pressangela@dovepress.com (Angela Jones)Dove Press Lung Cancer: Targets and TherapyLung Cancer: Targets and Therapyhttps://www.dovepress.com/feed/journal/83https://www.dovepress.com/assets/img/addon/rss-banner.jpg140140Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancerhttps://www.dovepress.com/exploratory-identification-of-gene-copy-number-cut-off-for-ngs-based-m-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyFri, 08 May 2026 21:20:00 +1200https://doi.org/10.2147/LCTT.S596080Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patientshttps://www.dovepress.com/efficiency-of-immunological-blood-biomarkers-in-predicting-chemotherap-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyMon, 16 Mar 2026 18:25:00 +1300https://doi.org/10.2147/LCTT.S578622Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Chinahttps://www.dovepress.com/prospective-observational-real-world-study-of-afatinib-as-first-line-t-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 18 Feb 2026 03:15:00 +1300https://doi.org/10.2147/LCTT.S555262Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancerhttps://www.dovepress.com/reduced-claudin-3-expression-is-linked-to-unfavorable-tumor-features-a-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 06 Jan 2026 00:00:00 +1300https://doi.org/10.2147/LCTT.S530791Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Reporthttps://www.dovepress.com/incretin-receptor-agonist-semaglutide-as-a-treatment-for-alectinib-ind-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyThu, 25 Dec 2025 05:00:00 +1300https://doi.org/10.2147/LCTT.S549011Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomicshttps://www.dovepress.com/integrated-multi-omics-approaches-for-predicting-immune-checkpoint-inh-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 16 Dec 2025 02:40:00 +1300https://doi.org/10.2147/LCTT.S539777Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimickerhttps://www.dovepress.com/pulmonary-nodular-lymphoid-hyperplasia-reviewing-a-lung-cancer-mimicke-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 10 Dec 2025 20:45:00 +1300https://doi.org/10.2147/LCTT.S527578A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025https://www.dovepress.com/a-concise-review-of-the-approved-met-tkis-savolitinib-gumarontinib-veb-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyFri, 31 Oct 2025 21:00:00 +1300https://doi.org/10.2147/LCTT.S547090Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnibhttps://www.dovepress.com/successful-and-on-going-long-term-disease-control-24-months-with-gilte-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 22 Oct 2025 16:20:00 +1300https://doi.org/10.2147/LCTT.S547128Tumor Heterogeneity and Plasticity in Small Cell Lung Cancerhttps://www.dovepress.com/tumor-heterogeneity-and-plasticity-in-small-cell-lung-cancer-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyFri, 10 Oct 2025 18:10:00 +1300https://doi.org/10.2147/LCTT.S511789Emerging Targets in Non-Small Cell Lung Cancerhttps://www.dovepress.com/emerging-targets-in-non-small-cell-lung-cancer-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapySat, 06 Sep 2025 17:15:00 +1200https://doi.org/10.2147/LCTT.S511767Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)https://www.dovepress.com/alectinib-efficacy-post-brigatinib-against-advanced-alk-non-small-cell-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 12 Aug 2025 23:00:00 +1200https://doi.org/10.2147/LCTT.S522038Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Sensitive Response to Afatinib: A Case Report and Literature Reviewhttps://www.dovepress.com/epidermal-growth-factor-receptor-kinase-domain-duplication-in-lung-ade-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 12 Aug 2025 02:00:00 +1200https://doi.org/10.2147/LCTT.S532278Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patientshttps://www.dovepress.com/genomic-and-transcriptomic-profiles-in-smokers-and-never-smokers-lung--peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapySat, 28 Jun 2025 19:10:00 +1200https://doi.org/10.2147/LCTT.S517580Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinomahttps://www.dovepress.com/evaluation-of-the-effectiveness-and-safety-profile-of-first-line-immun-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyMon, 09 Jun 2025 14:25:00 +1200https://doi.org/10.2147/LCTT.S494990Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cellshttps://www.dovepress.com/elucidating-the-role-of-fasn-in-lung-cancer-stem-cells-in-sensitive-an-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 27 May 2025 23:05:00 +1200https://doi.org/10.2147/LCTT.S512936LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)https://www.dovepress.com/laura-completes-the-osimertinib-treatment-jigsaw-puzzle-of-egfr-nsclc--peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyFri, 25 Apr 2025 19:15:00 +1200https://doi.org/10.2147/LCTT.S520833Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Studyhttps://www.dovepress.com/prevalence-of-egfr-mutations-in-vietnamese-patients-with-resected-earl-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyMon, 21 Apr 2025 18:30:00 +1200https://doi.org/10.2147/LCTT.S494554Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancerhttps://www.dovepress.com/impact-of-subsequent-treatment-on-clinical-outcomes-in-patients-with-e-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapySat, 12 Apr 2025 01:25:00 +1200https://doi.org/10.2147/LCTT.S516527Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survivalhttps://www.dovepress.com/genomic-profiling-of-extensive-stage-small-cell-lung-cancer-patients-i-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyThu, 20 Feb 2025 21:40:00 +1300https://doi.org/10.2147/LCTT.S492825Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLChttps://www.dovepress.com/comprehensive-survey-of-aacr-genie-database-of-tumor-mutation-burden-t-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 19 Feb 2025 23:10:00 +1300https://doi.org/10.2147/LCTT.S493835Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLChttps://www.dovepress.com/adagrasib-in-krystal-12has-not-broken-the-kras-g12c-enigma-code-of-the-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 17 Dec 2024 22:15:00 +1300https://doi.org/10.2147/LCTT.S492126Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinomahttps://www.dovepress.com/adagrasib-in-krystal-12has-broken-the-krasg12c-enigma-code-in-non-smal-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 30 Oct 2024 17:40:00 +1300https://doi.org/10.2147/LCTT.S490942Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Koreahttps://www.dovepress.com/real-world-outcomes-with-lurbinectedin-in-second-line-and-beyond-for-e-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 30 Oct 2024 17:25:00 +1300https://doi.org/10.2147/LCTT.S485320NRG1 Fusions in NSCLC: Being eNRGy Conscioushttps://www.dovepress.com/nrg1-fusions-in-nsclc-being-enrgy-conscious-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyThu, 03 Oct 2024 17:45:00 +1300https://doi.org/10.2147/LCTT.S464626Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literaturehttps://www.dovepress.com/pulmonary-spindle-cell-carcinoma-mimicking-granulomatous-inflammation--peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyThu, 29 Aug 2024 13:55:00 +1200https://doi.org/10.2147/LCTT.S480969Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancerhttps://www.dovepress.com/redefining-recovery-the-transformative-impact-of-the-alina-trial-on-ad-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyWed, 28 Aug 2024 17:20:00 +1200https://doi.org/10.2147/LCTT.S478054Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutationhttps://www.dovepress.com/mutation-of-met-d1228n-as-an-acquired-potential-mechanism-of-crizotini-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 27 Aug 2024 16:15:00 +1200https://doi.org/10.2147/LCTT.S467584Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?https://www.dovepress.com/spotlight-on-patritumab-deruxtecan-her3-dxd-from-herthena-lung01-is-a--peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapyTue, 09 Jul 2024 19:00:00 +1200https://doi.org/10.2147/LCTT.S467169Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.https://www.dovepress.com/top-20-egfr-nsclc-clinical-and-translational-science-papers-that-shape-peer-reviewed-fulltext-article-LCTTLung Cancer: Targets and TherapySat, 22 Jun 2024 02:30:00 +1200https://doi.org/10.2147/LCTT.S463429